Duration of untreated illness (DUI) and schizophrenia sub-types: A collaborative study between the universities of Milan and Moscow

Buoli, Massimiliano; Dell’Osso, Bernardo; Zaytseva, Yuliya; Gurovich, I.; Movina, Larisa; Дороднова, А. С.; Shmuckler, Alexander; Altamura, Alfredo Carlo

doi:10.1177/0020764012456807

Cited by 9 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DUI is a clinical variable of great interest in clinical practice because, unlike many other factors, it is modifiable by providing early diagnosis and treatment to the patient. It is well established that a prolonged DUI is associated with a poorer outcome not only in schizophrenia (Buoli et al, 2013), but also in mood disorders (Altamura et al, 2007), anxiety disorders (Altamura, Dell'osso, D'Urso, et al, 2008;Dell'Osso, Camuri, Benatti, Buoli, & Altamura, 2013) and obsessive-compulsive disorder(Dell'Osso, Buoli, Hollander, & Altamura, 2010). In our study, the average DUI was lower than that reported by most studies in the field, but consistent with the constant reduction of DUI over epochs of time observed in recent reports (Dell'Osso et al, 2016)(Dell'Osso et al, 2017, 2016.…”

Section: Discussionsupporting

confidence: 90%

Duration of untreated illness and depression severity are associated with cognitive impairment in mood disorders

Galimberti

Bosi

Volontè

et al. 2020

International Journal of Psychiatry in Clinical Practice

Self Cite

View full text Add to dashboard Cite

Introduction: In this study we estimated the rate and the trajectory of cognitive impairment in a naturalistic sample of outpatients with major depressive disorder (MDD) and bipolar disorder (BD) and its correlation with different variables. Materials and methods: An overall sample of 109 outpatients with MDD or BD was assessed for multiple clinical variables, including duration of untreated illness (DUI), and tested using the Montreal Cognitive Assessment (MoCA) during Major Depressive Episodes (MDE) and after remission. Correlations between MoCA scores and the clinical variables were then computed. Results: About 50% of patients with MDD and BD showed mild cognitive impairment during MDE. Improvement of cognitive function between depression and remission was significant, even though residual symptoms were observed especially in the most impaired patients. Of note, cognitive performance during depression was negatively associated with depression severity and DUI. Discussion: Present findings confirm available evidence about patterns of cognitive impairment in mood disorders, in terms of prevalence and persistence beyond remission in most severe cases. Moreover, a longer DUI was associated with worse cognitive performance during depression, and consequently with poorer outcome, underlining the importance of prompt treatment of these disorders also in light of a cognitive perspective.

show abstract

Section: Discussionsupporting

confidence: 90%

Duration of untreated illness and depression severity are associated with cognitive impairment in mood disorders

Galimberti

Bosi

Volontè

et al. 2020

International Journal of Psychiatry in Clinical Practice

Self Cite

View full text Add to dashboard Cite

show abstract

“…10,11 To date, DUI has been investigated across different psychiatric conditions, including major depressive disorder (MDD), 12,[13][14][15] bipolar disorder, 16 obsessive-compulsive disorder (OCD), [17][18][19] somatization, 20 eating, 21 and schizophrenia spectrum disorders. 8,[22][23][24] In respect to anxiety disorders, previous reports indicate a significantly shorter DUI compared to findings from studies conducted with patients with obsessive-compulsive, mood, and schizophrenia spectrum disorders. 9,25,26 Moreover, differences in terms of latency to treatment emerged between patients with PD and generalized anxiety disorder, with PD patients having a shorter DUI.…”

Section: Introductionmentioning

confidence: 85%

Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Panic disorder (PD) is a prevalent and impairing anxiety disorder with previous reports suggesting that the longer the condition remains untreated, the greater the likelihood of nonresponse. However, patients with PD may wait for years before receiving a guideline-recommended pharmacological treatment. The widespread prescription of benzodiazepines (BDZ) for managing anxiety symptoms and disorders might delay the administration of pharmacotherapy according to guidelines (eg, selective serotonin reuptake inhibitors, SSRIs). The present study aimed to determine the mean duration of untreated illness (DUI) in a sample of PD patients, to quantify and compare DUI-SSRI to DUI-BDZ, and to compare findings with those from previous investigations. Methods Three hundred and fourteen patients with a Diagnostic and Statistical Manual of Mental Disorders, fifth edition diagnosis of PD were recruited from an Italian outpatient psychotherapy unit, and epidemiological and clinical variables were retrieved from medical records. Descriptive statistical analyses were undertaken for sociodemographic and clinical variables, Wilcoxon matched-pair signed rank test was applied to compare the distribution of DUI-SSRI vs DUI-BDZ, and Welch’s t test was performed to compare findings with those from previous studies. Results The mean DUI-SSRI of the total sample was 64.25 ± 112.74 months, while the mean DUI-BDZ was significantly shorter (35.09 ± 78.62 months; P < 0.0001). A significantly longer DUI-SSRI, compared to findings from previous studies, was also observed. Conclusions The present results confirm a substantial delay in implementing adequate pharmacological treatments in patients with PD, and highlight the discrepancy between recommendations from international treatment guidelines and common clinical practice in relation to BDZ prescription.

show abstract

“…Of note, in our analyses the duration of illness refers to the duration of substance use disorder, and the duration of untreated illness (DUI) is defined as the time between the onset of psychotic symptoms and the administration of an antipsychotic compound [ 32 ].…”

Section: Methodsmentioning

confidence: 99%

Clinical Variables and Peripheral Biomarkers Associated with Substance-Induced Psychotic Disorder: Differences Related to Alcohol, Cannabis, and Psychostimulant Abuse

Di Paolo,

Calabrese,

Nosari

et al. 2024

JPM

Self Cite

View full text Add to dashboard Cite

Background: The present retrospective observational study aims to identify differences in clinical features and peripheral biomarkers among patients affected by substance-induced psychotic disorder (SIPD) according to the primary substance of abuse. Methods: A sample of 218 patients was divided into three groups according to the type of consumed substance: alcohol, cannabis, and psychostimulants. The three groups were compared using one-way analyses of variance (ANOVAs) for continuous variables and χ2 tests for qualitative variables. After excluding the alcohol-induced psychotic disorder group, the same analyses were repeated. The statistically significant variables from these subsequent analyses were included in a binary logistic regression model to confirm their reliability as predictors of cannabis- or psychostimulant-induced psychotic disorder. Results: Psychotic cannabis abusers were younger (p < 0.01), with illness onset at an earlier age (p < 0.01). Alcohol consumers presented a longer duration of illness (p < 0.01), more frequent previous hospitalizations (p = 0.04) and medical comorbidities (p < 0.01), and higher mean Modified Sad Persons Scale scores (p < 0.01). Finally, psychostimulant abusers had a higher frequency of lifetime history of poly-substance use disorders (p < 0.01). A binary logistic regression analysis revealed that higher mean Brief Psychiatric Rating Scale scores (p < 0.01) and higher sodium (p = 0.012) and hemoglobin (p = 0.040) plasma levels were predictors of cannabis misuse in SIPD patients. Conclusions: Different clinical factors and biochemical parameters con be associated with SIPD according to the main substance of abuse, thus requiring specific management by clinicians.

show abstract

Duration of untreated illness (DUI) and schizophrenia sub-types: A collaborative study between the universities of Milan and Moscow

Abstract: The results of the present study suggest that the different schizophrenic sub-types may differ in terms of DUI, likely due to different clinical severity and social functioning. Studies with larger samples are needed to confirm the data of the present study.

Cited by 9 publications

References 37 publications

Duration of untreated illness and depression severity are associated with cognitive impairment in mood disorders

Duration of untreated illness and depression severity are associated with cognitive impairment in mood disorders

Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study

Clinical Variables and Peripheral Biomarkers Associated with Substance-Induced Psychotic Disorder: Differences Related to Alcohol, Cannabis, and Psychostimulant Abuse

Contact Info

Product

Resources

About